School of Pediatrics


GENG Hongquan



Office Phone:021-25078460

Research Interests

  • Gene therapy for urinary calculi caused by PH1

  • Etiology and cohort study on pediatric hydronephrosis


  • Chief surgeon

  • Doctoral tutor

  • Head of pediatric urology of Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

  • Head of Pediatric urinary Calculi Treatment Center of National Health Council

Educational Experience

  • 1991.9-1996.7:Shanghai Second Medicine School, Bachelor of Medicine

  • 2000.9-2003.7:Shanghai Second Medicine School, Master of Medicine

  • 2005.9-2006.7:Baylor College of Medicine & Texas Children's Hospital, Visiting scholar

  • 2009.9-2012.7:Shanghai Jiao Tong University School of Medicine, PhD

Membership in Academic Society

  • Member of Division of Pediatric Urology, Society of Pediatric Surgery, Chinese Medical Association

Research projects

  • 2008.11-2011.10:Shanghai Science and Technology Commission, Study on the bladder original matrix with long-term sustained release growth factor as bladder substitute material

  • 2009.9-2010.12:Small Amount Discovery Program of Natural Science Foundation of China, An experimental study on bladder regeneration induced by collagen matrix tablets with long-term sustained release of growth factors

  • 2012.1-2015.12:Natural Science Foundation of China, Research on functional protein-modified bladder acellular matrix as bladder replacement material

  • 2016.1-2018.12:Research Physician Program of Shanghai Jiao Tong University School of Medicine, Study on the mechanism and prognosis of congenital hydronephrosis

  • 2018.1-2020.12:Training Program of Shanghai Municipal Health Commission, Construction of a rat model of PH1 and research on gene therapy

  • 2018.1-2021.12:Natural Science Foundation of China, Using gene editing technology to construct a rat PH1 model and carry out gene therapy research

  • 2018.5-2021.4:Academic leadership project of Shanghai Science and Technology Commission, Mechanism of thymosin β4 promoting MSC-derived exosomes and intervening in renal interstitial fibrosis


  1. Jiang D, Geng H*. Primary Hyperoxaluria. N Engl J Med. 2017;376(15):e33.

  2. Zheng, R., Fang, X., Chen, X., Huang, Y., Xu, G., He, L., Li, Y., Niu, X., Yang, L., Wang, L., Li, D., & Geng, H*. (2020). Knockdown of lactate dehydrogenase by adeno-associated virus-delivered CRISPR/Cas9 system alleviates primary hyperoxaluria type 1. Clinical and translational medicine, 10(8), e261.

  3. Zheng, R., Li, Y., Wang, L., Fang, X., Zhang, J., He, L., Yang, L., Li, D., & Geng, H*. (2020). CRISPR/Cas9-mediated metabolic pathway reprogramming in a novel humanized rat model ameliorates primary hyperoxaluria type 1. Kidney international, 98(4), 947–957.

  4. He, L., Xu, G., Fang, X., Lin, H., Xu, M., Yu, Y., & Geng, H*. (2019). Identification of 8 novel gene variants in primary hyperoxaluria in 21 Chinese children with urinary stones. World journal of urology, 37(8), 1713–1721.

  5. Zhao, Y., Fang, X., Fan, Y., Sun, Y., He, L., Xu, M., Xu, G., Li, Y., Huang, Y., Yu, Y., & Geng, H*. (2021). Integration of exome sequencing and metabolic evaluation for the diagnosis of children with urolithiasis. World journal of urology, 39(7), 2759–2765.

  6. Chen, H., Lin, H., Xu, M., Xu, G., Fang, X., He, L., Chen, Z., Wu, Z., & Geng, H*. (2019). Quantitative Urinary Proteome Reveals Potential Biomarkers for Ureteropelvic Junction Obstruction. Proteomics. Clinical applications, 13(4), e1800101.

  7. Li, Y., Zheng, R., Xu, G., Huang, Y., Li, Y., Li, D., & Geng, H*. (2021). Generation and characterization of a novel rat model of primary hyperoxaluria type 1 with a nonsense mutation in alanine-glyoxylate aminotransferase gene. American journal of physiology. Renal physiology, 320(3), F475–F484.

  8. Li, Y., Chen, Z., Zhang, J., Zhang, Q., He, L., Xu, M., Xu, G., Geng, H*., & Fang, X. (2020). Quantitative Proteome of Infant Stenotic Ureters Reveals Extracellular Matrix Organization and Oxidative Stress Dysregulation Underlying Ureteropelvic Junction Obstruction. Proteomics. Clinical applications, 14(6), e2000030.

  9. Zhao, Y., Fang, X., He, L., Fan, Y., Li, Y., Xu, G., Yu, Y., & Geng, H*. (2022). A comparison of the clinical characteristics of pediatric urolithiasis patients with positive and negative molecular diagnoses. World journal of urology, 40(5), 1211–1216.

  10. Fang, X., He, L., Xu, G., Lin, H., Xu, M., & Geng, H*. (2019). Nine novel HOGA1 gene mutations identified in primary hyperoxaluria type 3 and distinct clinical and biochemical characteristics in Chinese children. Pediatric nephrology (Berlin, Germany), 34(10), 1785–1790.

  11. Chen, Z., Lin, H., Xu, M., Xu, G., Fang, X., He, L., & Geng, H*. (2020). The clinical manifestations of intermittent hydronephrosis and their relationship with renal function in pediatric patients. Journal of pediatric urology, 16(4), 458.e1–458.e6.